This unique series of four live, one day meetings will provide expert reviews of the most meaningful and practice changing data in the field of hematologic malignancies presented at ASH and other major society meetings held throughout 2008. In addition to didactic lectures, the format of the meeting also includes interactive “The Smartest Oncologist/Hematologist Quizzes”.

7:00 am-8:00 am	Registration and Breakfast
8:00 am-8:10 am	Welcome and Introduction
8:10 am-8:20 am	Smartest Oncologist/Hematologist Quiz
8:20 am-8:50 am	Multiple Myeloma: Frontline Therapy
8:50 am-9:20 am	Multiple Myeloma: Relapsed/Refractory
9:20 am-9:50 am	Indolent Non-Hodgkin Lymphoma
9:50 am-10:20 am	Aggressive Non-Hodgkin Lymphoma
10:20 am-10:45 am	Break
10:45 am-10:55 am	Smartest Oncologist/Hematologist Quiz
10:55 am-11:25 am	Hodgkin Disease
11:25 am-12:05 pm	Chronic Myelogenous Leukemia
12:05 pm-12:35 pm	Chronic Lymphocytic Leukemia
12:35 pm-1:35 pm	Lunch
1:35 pm-1:45 pm	Smartest Oncologist/Hematologist Quiz
1:45 pm-2:15 pm	Myelodysplastic Syndromes
2:15 pm-2:45 pm	Myeloproliferative Disorders
2:45 pm-3:15 pm	Acute Leukemia
3:15 pm-3:30 pm	Concluding Remarks
3:30 pm	Adjourn

Washington, D.C. Kenneth C. Anderson, MD Fernando Cabanillas, MD Susan O’Brien, MD Robert Z. Orlowski, MD, PhD Mikkael Sekeres, MD, MS Neil Shah, MD, PhD Richard Stone, MD David J. Straus, MD Ayalew Tefferi, MD Julie Vose, MD New York, New York Kenneth C. Anderson, MD Fernando Cabanillas, MD Jorge Cortes, MD John P. Leonard, MD Robert Z. Orlowski, MD, PhD Kanti R. Rai, MD Mikkael Sekeres, MD, MS David J. Straus, MD Ayalew Tefferi, MD Meir Wetzler, MD

Houston, Texas Jorge Cortes, MD Guillermo Garcia-Manero, MD Peter McLaughlin, MD Ruben Mesa, MD Susan O’Brien, MD Robert Z. Orlowski, MD, PhD S. Vincent Rajkumar, MD David J. Straus, MD Meir Wetzler, MD Atlanta, Georgia Kenneth C. Anderson, MD James O. Armitage, MD Jorge Cortes, MD Sagar Lonial, MD Susan O’Brien, MD Mikkael Sekeres, MD, MS Wendy Stock, MD David J. Straus, MD Ayalew Tefferi, MD Andrew D. Zelenetz, MD

Hagop Kantarjian, MD (Series Chair) The University of Texas M.D. Anderson Cancer Center Houston, Texas Al Soltan, MD (Moderator) Georgia Cancer Specialists Atlanta, Georgia Stan Winokur, MD (Moderator) Winokur Consulting Group West Palm Beach, Florida Kenneth C. Anderson, MD Dana-FarbercCancer Institute Boston, Massachusetts James O. Armitage, MD University of Nebraska Omaha, Nebraska Fernando Cabanillas, MD Auxilio Mutuo Cancer Center San Juan, Puerto Rico Jorge Cortes, MD The University of Texas M.D. Anderson Cancer Center Houston, Texas Guillermo Garcia-Manero, MD The University of Texas M.D. Anderson Cancer Center Houston, Texas John P. Leonard, MD Weill Medical College of Cornell University New York, New York Sagar Lonial, MD Emory University Atlanta, Georgia Peter McLaughlin, MD The University of Texas M.D. Anderson Cancer Center Houston, Texas Ruben Mesa, MD Mayo Clinic Rochester, Minnesota Susan O'Brien, MD The University of Texas M.D. Anderson Cancer Center Houston, Texas

Robert Z. Orlowski, MD, PhD The University of Texas M.D. Anderson Cancer Center Houston, Texas Kanti R. Rai, MD Long Island Jewish Medical Center New Hyde Park, New York S. Vincent Rajkumar, MD Mayo Clinic Rochester, Minnesota Mikkael Sekeres, MD, MS Cleveland Clinic Cleveland, Ohio Wendy Stock, MD University of Chicago Chicago, Illinois Richard Stone, MD Dana-Farber Cancer Institute Boston, Massachusetts Neil Shah, MD, PhD University of California, San Francisco San Francisco, California David J. Straus, MD Memorial Sloan-Kettering Cancer Center New York, New York Ayalew Tefferi, MD Mayo Clinic Rochester, Minnesota Julie Vose, MD University of Nebraska Omaha, Nebraska Meir Wetzler, MD Roswell Park Cancer Center Institute Buffalo, New York Andrew D. Zelenetz, MD Memorial Sloan-Kettering Cancer Center New York, New York

Washington, D.C. The Westin Grand, Washington D.C. 2350 M Street NW Washington, DC 20037 New York, New York The Roosevelt Hotel Madison Avenue at 45th Street New York, NY 10017

Houston, Texas Hilton Americas-Houston 1600 Lamar Street Houston, TX 77010 Atlanta, Georgia W Atlanta – Buckhead 3377 Peachtree Road NE Atlanta, GA 30326

Who Should Attend
This educational activity is intended for oncologists, hematologists, physicians, internists, and other healthcare professionals interested in the management of hematologic malignancies.

Statement of Need
As the rate at which clinical data is released increases and the numbers of therapeutic options grow, it is important for practicing oncologists and hematologists to stay abreast of these advances. Many community oncologists, hematologists and other physicians involved in the management of hematologic malignancies do not attend major society meetings and likewise those who do, find the size and scope to be so broad and intensive that they require summaries of important data for ease of application to their daily practices. In order for rapid clinical progress to have a direct and immediate impact on patients’ lives, the newest findings must be readily applied by the practices of community oncologists. In addition, the data presented at large clinical conferences is typically not framed in the context of the clinical practices of the community oncologists. PRIME Oncology presents “Hematologic Malignancies Demystified: The Series” A Critical Appraisal of Data from 2008 and ASH, to review, summarize, and interpret the most clinically significant data in an effort to meet this need.

Educational Objectives
Upon completion of this educational activity, participants should be better able to:

• Describe the latest management approaches for hematologic malignancies including leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes and myeloproliferative disorders
• Explain difficult or unusual problems encountered by the practicing hematologist/oncologist
• Identify appropriate management options based on emerging data
• Discuss issues surrounding the design and conduct of clinical trials that incorporate novel agents and/or regimens for patients with hematologic malignancies
• Summarize emerging data in the management of multiple hematologic malignancies
• Integrate new findings into clinical practice

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine (PIM) and PRIME Oncology. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
PIM designates this educational activity for a maximum of 6 AMA PRA Category 1 Credit(s)™ per activity. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
PIM and PRIME Oncology assess conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM and PRIME Oncology for fair balance, scientific objectivity of studies utilized in this activity and patient care recommendations. PIM and PRIME Oncology are committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Fee for Activity

• Regular Registration: $75.00
• Onsite Registration: $100.00
• Nurses/Students/Fellows: $35.00*
• Onsite Nurses/Students/Fellows: $50.00*

*Supporting documentation of eligibility may be required.

Pre-registration will close on the following days for each program:

• Washington, D.C. – January 21, 2009
• Houston, Texas – January 28, 2009
• New York, New York – February 4, 2009
• Atlanta, Georgia – February 18, 2009

The registration fee includes all program materials, continental breakfast, lunch, and refreshment breaks. PRIME Oncology does not accept liability for travel, accommodations, or any other costs incurred by registrants.



Cancellation/Substitutions Policy
The registration fee is non-refundable. Substitutions will be accepted up to one week prior to the meeting date with written notice.


Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Kim Friese prior to the live event at (678) 892-1340 or kim.friese@primeoncology.org.